Clinical trials: Progression Free Survival
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of advanced Hepatocellular Carcinoma
- Trial name
- NCT05282433
- Testing
- Surufatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhongnan Hospital
Colorectal Cancer, Circulating Tumor DNA
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
A open label 1:1 randomized phase II exploratory study investigating adjuvant therapy in patients with molecular biologically detectable residual disease after primary resection for localized colorectal tumors.
- Conditions
- Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy, Progression Free Survival
- Trial name
- IMPROVE-IT (NCT03748680)
- Testing
- Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule
- Where
- 4 sites in Denmark
- Volunteers
- 64 people
- Sponsor
- Karen-Lise Garm Spindler
Progression-free Survival, Gastrointestinal Stromal Tumor
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved.
- Conditions
- Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
- Trial name
- ZJGIST-01 (NCT04933669)
- Testing
- Imatinib
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Recurrent Cervical Carcinoma, Radiotherapy
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the survival periods.
- Conditions
- Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab
- Trial name
- NCT04664244
- Testing
- Combination of nimotuzumab and radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Lei Li
Progression-free Survival, Overall Survival
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine.
- Conditions
- Progression-free Survival, Overall Survival, Toxicity
- Trial name
- PDVPSTS (NCT03342300)
- Testing
- pegylated liposomal doxorubicin, pirarubicin
- Where
- China
- Sponsor
- Peking University People's Hospital
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Meningioma Atypical, Radiotherapy
Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection
Postoperative adjuvant radiotherapy is a key component of comprehensive treatment of meningioma. However, for atypical meningioma after total resection, there is still a huge controversy in patients who need adjuvant radiotherapy…
- Conditions
- Meningioma Atypical, Radiotherapy, Progression-Free Survival, Adverse Effect of Radiation Therapy
- Trial name
- NCT04127760
- Testing
- radiotherapy
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li
Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy
A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Epithelial ovarian carcinomatous and borderline components sometimes appeared in one patient. This study aims to analyze the genomic patterns of the carcinomatous and borderline components in the ovarian epithelial tissues.
- Conditions
- Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy, Driving Mutations, Progression-free Survival
- Trial name
- NCT03742388
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei Li
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety
Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial
Gastric cancer is the one of the leading cause of cancer death in the worldwide. Gastric cancer originates from the most superficial mucosal epithelial cells of the stomach wall, which can occur in various parts of the stomach…
- Trial name
- NCT03531931
- Testing
- Apatinib/Capecitatine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Progression Free Survival
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in non-small cell lung cancer.
- Trial name
- NCT02959749
- Testing
- Osimertinib, docetaxel, bevacizumab
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Qingdao Central Hospital
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Progression-Free-Survival, Recurrence
Clinical Study on Triple Negative Breast Cancer With Chinese Medicine
Breast cancer is one of the most serious threat to women's health of malignant tumors, also the most common causes of cancer death in women.Triple-negative breast cancer (TNBC) refers to the immunohistochemical detection of…
- Conditions
- Progression-Free-Survival, Recurrence, Overall Survival
- Trial name
- NCT03332368
- Testing
- Traditional Chinese medicine
- Where
- 5 sites in China
- Volunteers
- 620 people
- Sponsor
- Sheng Liu
Progression Free Survival
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib
- Trial name
- NCT03100955
- Testing
- cisplatin, etoposide, cisplatin, etoposide, apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qingdao University
Progression Free Survival of the Treatment
IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC
This is a prospective, single-armed, open label study on the efficacy and safety of sequential IP therapy(Irinotecan plus cisplatin) and octreotide lar in the treatment of GI poorly diffrentiated Neuroendocrine carcinoma.
- Trial name
- NCT01480986
- Testing
- Irinotecan combined with cisplatin, octreotide lar
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Progression Free Survival
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
Treatment options for patients with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case.
- Trial name
- TT (NCT01453257)
- Testing
- Tailored Chemotherapy
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Grupo Hospital de Madrid
Progression-free Survival
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who…
- Trial name
- NCT00944918
- Testing
- fulvestrant, anastrozole, exemestane
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- AstraZeneca